Drug intelligence / Profile preview

RapVac-2302

Development stage: Preclinical
Lead developer: RAPHAS
Modality: Vaccines & Immunotherapeutics
Administration: Transdermal

Overview

RapVac-2302 is a preclinical-stage vaccine candidate developed by RAPHAS for the prevention of hepatitis B virus (HBV) infection. It utilizes RAPHAS's proprietary dissolvable microneedle patch technology to deliver hepatitis B surface antigen (HBsAg) transdermally. The vaccine is designed to stimulate the immune system to generate protective antibodies against HBsAg, offering a potentially painless and stable alternative to traditional needle-and-syringe vaccinations. The microneedle delivery system aims to enhance patient compliance and eliminate the need for cold-chain logistics typically required for liquid vaccines.

Other names: RapVac-2302RapVac2302RapVac 2302

Targets

HBsAg (Hepatitis B surface antigen)

Beyond the preview

Go deeper on RapVac-2302.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RapVac-2302.

Explore the full profile